Opendata, web and dolomites

LEGACy SIGNED

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LEGACy project word cloud

Explore the words cloud of the LEGACy project. It provides you a very rough idea of what is the project "LEGACy" about.

histological    pylori    contrast    strains    respectively    helicobacter    differences    makeup    genome    bacterium    epidemiology    723    multicentre    secondary    health    eastern    gc    infection    women    incidence    cancer    lowest    barr    northern    gastric    countries    sharp    integrative       asian    epstein    deaths    vary    molecular    databases    worldwide    virus    revolutionized    multiple    globally    central    tumour    epidemiological    participating    sexes    personalized    intervention    susceptibility    america    primary    similarly    strategy    omics    strategies    ebv    genetic    highest    treatments    locally    outcomes    populations    plays    patients    location    standpoint    men    poorly    model    24    medicine    dietary    gcs    prevention    largely    10    stage    legacy    celac    prognosis    conceptual    urgent    arrival    south    disease    positive    total    international    mortality    biology    death    extended    levels    rates    none    public    asia   

Project "LEGACy" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA 

Organization address
address: AV MENENDEZ PELAYO 4
city: VALENCIA
postcode: 46010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙993˙056 €
 EC max contribution 3˙577˙431 € (90%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA ES (VALENCIA) coordinator 638˙315.00
2    IPATIMUP - INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP PT (PORTO) participant 660˙162.00
3    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 550˙000.00
4    STICHTING VUMC NL (AMSTERDAM) participant 471˙875.00
5    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 305˙235.00
6    ANAXOMICS BIOTECH, S.L. ES (BARCELONA) participant 275˙218.00
7    CABALLERO LLANO CARMELO CESAR PY (ASUNCION) participant 216˙093.00
8    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 197˙750.00
9    ALEXANDER FLEMING SA AR (BUENOS AIRES) participant 131˙625.00
10    UNIVERSITAET LEIPZIG DE (LEIPZIG) participant 131˙156.00
11    Instituto Nacional de Cancerología MX (MEXICO) participant 0.00

Map

 Project objective

Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in women), the lowest in Northern America (2.8 and 1.5, respectively). High mortality rates are also present in both sexes in Central and Eastern Europe, and in Central and South America. None strategies have improved prognosis in locally advanced stage III and IV GC. Therefore, an urgent intervention is needed. Epidemiological and molecular features of GCs can vary widely according to their histological type, location and genetic makeup of the tumour. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori) and dietary factors. In particular, H. pylori infection plays a relevant role in GC incidence. Similarly, about 10% of GC patients are positive for the infection of the Epstein Barr Virus (EBV) . Most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU and CELAC countries is poorly known. From a public health standpoint, prevention can be conducted at three levels: primary, secondary, and for improving outcomes at the advanced stage of disease. In recent years, the arrival of personalized medicine has revolutionized available treatments for cancer patients. The primary aim of LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention: in EU and CELAC countries participating in this multicentre case-control study based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEGACY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEGACY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More